Literature DB >> 15942707

Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.

Kou-Gi Shyu1, Jer-Young Liou, Bao-Wei Wang, Wei-Jen Fang, Hang Chang.   

Abstract

The use of beta-blockers has emerged as a beneficial treatment for cardiac hypertrophy. Hypoxia-inducible factor-1alpha (HIF-1alpha) is tightly regulated in the ventricular myocardium. However, the expression of HIF-1alpha in cardiac hypertrophy due to pressure overload and after treatment with beta-blocker is little known. To evaluate the effect of carvedilol on both myocardial HIF-1alpha expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Carvedilol at 50 mg/kg body weight per day after surgery was given. Heart weight and the ratio of heart weight and body weight increased significantly after aortic banding for 4 weeks in the absence of drug treatment. Mean arterial pressure increased from 80 +/- 9 mmHg in the sham group to 94 +/-5 mmHg (p < 0.001) in the banding group. Echocardiography showed concentric hypertrophy after aortic banding. Mean arterial pressure decreased after treatment with carvedilol. The increased wall thickness and heart weight was reversed to normal by carvedilol. Western blot showed that HIF-1alpha, vascular endothelial growth factor (VEGF) and brain natriuretic peptide (BNP) proteins were up-regulated and nerve growth factor-beta (NGF-beta) down-regulated in the banding group. Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and VEGF proteins expression in the banding groups. Real-time polymerase chain reaction showed that mRNA of HIF-1alpha, VEGF and BNP increased and mRNA of NGF-beta decreased in the banding group. Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values. Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling. In conclusion, HIF-1alpha, VEGF, and BNP mRNA and protein expression were up-regulated, while NGF-beta mRNA and protein was downregulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and NGF-beta in the hypertrophic myocardium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942707     DOI: 10.1007/s11373-005-3008-x

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  31 in total

Review 1.  Complex role of the HIF system in cardiovascular biology.

Authors:  Gabor Czibik
Journal:  J Mol Med (Berl)       Date:  2010-06-24       Impact factor: 4.599

2.  Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes.

Authors:  Tao Tan; Peter M Scholz; Harvey R Weiss
Journal:  Life Sci       Date:  2010-05-12       Impact factor: 5.037

3.  Effects of carvedilol reduce conjunctivitis through changes in inflammation, NGF and VEGF levels in a rat model.

Authors:  Ying Chen; Xianfei Hong
Journal:  Exp Ther Med       Date:  2016-03-10       Impact factor: 2.447

Review 4.  [Current aspects of eyelid, lacrimal and orbital surgery in childhood].

Authors:  G Avgitidou; K R Koch; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

5.  Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload.

Authors:  Yasuhiro Izumiya; Ichiro Shiojima; Kaori Sato; Douglas B Sawyer; Wilson S Colucci; Kenneth Walsh
Journal:  Hypertension       Date:  2006-03-27       Impact factor: 10.190

6.  Ca(2+) channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats.

Authors:  Takao Nishizawa; Xian Wu Cheng; Zhehu Jin; Koji Obata; Kohzo Nagata; Akihiro Hirashiki; Takeshi Sasaki; Akiko Noda; Kyosuke Takeshita; Hideo Izawa; Guo-Ping Shi; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

7.  Ocular Safety of Intravitreal Propranolol and Its Efficacy in Attenuation of Choroidal Neovascularization.

Authors:  Ramin Nourinia; Mozhgan Rezaei Kanavi; Amir Kaharkaboudi; Seyed Iman Taghavi; Seyed Javid Aldavood; Soesiawati R Darjatmoko; Shoujian Wang; Zafer Gurel; Jeremy A Lavine; Sare Safi; Hamid Ahmadieh; Narsis Daftarian; Nader Sheibani
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

8.  Protective effect of olmesartan against cardiac ischemia/reperfusion injury in spontaneously hypertensive rats.

Authors:  Xin Lu; Yan-Wen Bi; Ke-Biao Chen; Hong-Yue Wang
Journal:  Exp Ther Med       Date:  2015-03-20       Impact factor: 2.447

9.  Periocular capillary hemangiomas: indications and options for treatment.

Authors:  Genie M Bang; Pete Setabutr
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

10.  Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers.

Authors:  Brian D Lowes; Ronald Zolty; Simon F Shakar; Andreas Brieke; Norman Gray; Michael Reed; Mihail Calalb; Wayne Minobe; JoAnn Lindenfeld; Eugene E Wolfel; Mark Geraci; Michael R Bristow; Joseph Cleveland
Journal:  J Heart Lung Transplant       Date:  2007-11       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.